An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19

Схожие документы

• Immunoglobulin G glycome and severity of COVID-19: more likely a quantification of bias than a true association. A comment on Petrović et al., “Composition of the immunoglobulin G glycome associates with the severity of COVID-19”
  по: Trkulja, Vladimir, et al.
  Опубликовано: (2020)
• Proton pump inhibitors increase risk of COVID-19
  Опубликовано: (2020)
• Risk of COVID-19 in Patients Taking Proton Pump Inhibitors
  по: Hadi, Yousaf B., et al.
  Опубликовано: (2020)
• Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?
  по: Charpiat, Bruno, et al.
  Опубликовано: (2020)
• Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID‐19: coincidence or underestimated risk factor?
  по: Luxenburger, H., et al.
  Опубликовано: (2020)